Vifor Pharma to acquire Sanifit, supported, among other investors, by Ysios Capital, Caixa Capital Risc, Columbus Venture Partners and Alta Life Sciences

by Caixa Capital Risc

Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the company

Read more

Sanifit Therapeutics será adquirida por la farmacéutica Vifor Pharma

by Columbus Venture Partners

Damià Tormo, Managing Partner de Columbus Venture Partners: “El equipo de Sanifit ha conseguido llevar un proyecto de investigación desde la investigación básica de la Universidad de Islas Balea...

Read more

Aura Biosciences sale a bolsa en el NASDAQ

by Columbus Venture Partners

Columbus Venture Partners ha apoyado a la compañía desde la serie B, a través de su fondo Columbus INNVIERTE Life Science FCR, así como en la serie «pre OPS» que tuvo lugar en marzo de 2021 y en...

Read more

NeRRe Therapeutics raises £20 million in a Series B2 financing round

by Columbus Venture Partners

The financing round involved a syndicate of leading transatlantic life sciences investors led by new investor Columbus Venture Partners andexisting investors Advent Life Sciences, Fountain Healthcare ...

Read more

Arcline Investment Management Acquires Polypeptide Therapeutic Solutions from Columbus Venture Partners

by Columbus Venture Partners

Arcline Investment Management, a growth-oriented private equity firm with $4.3 billion of cumulative capital commitments, today announced the acquisition of Polypeptide Therapeutic Solutions, S.L. fr...

Read more

Columbus Venture Partners eleva el cierre de su tercer fondo a €120 millones

by Columbus Venture Partners

Este es el tercer fondo de la firma de capital riesgo después del lanzamiento de su primer fondo en abril de 2016 con €41 millones de euros, y un segundo fondo lanzado en febrero de 2019 con €74 ...

Read more

Vivet Therapeutics, supported by Ysios Capital and Columbus Venture, closes an exclusive license option with Mirum Pharmaceuticals

by Ysios Capital

Vivet’s second gene therapy product, VTX-803 for PFIC3, received US and European Orphan Drug Designation in May 2020.Vivet is supported by international life science investors including Novartis Ven...

Read more

Aura Biosciences, supported by Ysios Capital, Announces Oversubscribed $80 Million Financing

by Ysios Capital

Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the closing of an oversubsc...

Read more

Almirall and Tyris Therapeutics, founded by Columbus Venture Partners, enter into strategic partnership to develop next generation gene therapies

by Columbus Venture Partners

Almirall, S.A., a global biopharmaceutical company based in Barcelona, and Tyris Therapeutics, a next generation gene therapy company founded by Columbus Venture Partners, have announced a strategic p...

Read more

Columbus Venture Partners prepara su tercer fondo biotech de hasta €100 millones

by Columbus Venture Partners

La gestora de capital riesgo especializada en biotecnología Columbus prepara su tercer vehículo de inversión. La previsión es que el fondo alcanzará un tamaño de entre 80 millones y 100 millones...

Read more

Bayer acquires Asklepios BioPharmaceutical for $4 billion

by Columbus Venture Partners

AskBio is a veteran of the gene therapy space. Jude Samulski, a pioneer of AAV vectors, founded the company in 2001. Since then, AskBio has built out an AAV platform and an associated high-yield cell ...

Read more

Algenex cierra nueva ronda de financiación por 7,4 millones para afrontar sus nuevos proyectos en salud humana

by Columbus Venture Partners

La compañía biotecnológica Algenex ha cerrado una ronda de financiación privada por valor de 7,4 millones de euros liderada por MasterLux, inversor asesorado por Cleon Capital y Vita Advisory. Est...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

ALBIA IMAP advises AKT on its sale to CI...

by Albia Capital Partners

CIE AUTOMOTIVE, Global supplier of components, assemblies and sub-asse...

Photos Stream